TOP EMINENT HEALTHCARE

Top Eminent Healthcare Group Limited
（卓著健康集團有限公司）*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6877)

CHANGE OF DIRECTORS
AND
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS

CHANGE OF DIRECTORS

The board (the "**Board**") of directors (the "**Director(s)**") of Top Eminent Healthcare Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") hereby announces the following changes in the composition of the Board:

(a) Mr. Li Jiong ("**Mr. Li**") will resign as a non-executive Director of the Company with effect from 30 June 2026 due to other business engagements requiring his full attention.

(b) Ms. Wang Yinqing ("**Ms. Wang**") will be appointed as an executive Director of the Company with effect from 1 July 2026.

Mr. Li has confirmed that he has no claims against the Company, no disagreement with the Board, and is not aware of any matters that need to be brought to the attention of the Company's shareholders or The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") in relation to his resignation. The Board would like to express its sincere gratitude to Mr. Li for his valuable contributions to the Company during his tenure of office.

<u>Biographical Details of Ms. Wang Yinqing</u>

Ms. Wang Yinqing – Executive Director

Ms. Wang Yinqing, aged 43, has over 21 years of experience in international trade within the healthcare industry. From August 2006 to October 2015, Ms. Wang worked at China International Pharmaceutical Health Co., Ltd.* （中國國際醫藥衛生公司）, where she last served as assistant to the chairman of the health business department and was primarily responsible for the export of pharmaceutical raw materials, import of health food, and domestic channel sales. Since October 2015, Ms. Wang has joined Beijing Tong Ren Tang International Information Technology Co., Ltd.*（北京同仁堂國際信息技術有限公司）which is a subsidiary of Beijing Tong Ren Tang (Cayman) Limited, the controlling shareholder of the Company (as defined under the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**")), and is currently the vice president and president of the e-commerce business department. She is responsible for the cross-border e-commerce business segment, including product development, market expansion, and brand operations for dietary supplements and health food, as well as the wholesale of proprietary Chinese medicines.

As at the date of this announcement and save as disclosed above, Ms. Wang (i) has not held any other directorships in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) has not held any other position with the Company and other subsidiaries of the Group; and (iii) does not have any other major appointments or professional qualifications. Ms. Wang has not been involved in any bankruptcy, insolvency, liquidation, receivership, or been a director of any company that has been subject to such proceedings, nor has she been convicted of any criminal offence or subject to any regulatory sanctions. Ms. Wang has confirmed that she has not been involved in any matters required to be disclosed under Rules 13.51(2)(h) to (v) of the Listing Rules.

Relationships and Shareholding Interests

Ms. Wang has no relationship with any Directors, senior management, substantial shareholders or controlling shareholders (as defined in the Listing Rules) of the Company. As at the date of this announcement, Ms. Wang does not have, nor is deemed to have, any interests or short positions in any shares, underlying shares or debentures of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "**SFO**") as recorded in the register required to be kept under section 352 of the SFO or as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers.

Director's Emoluments and Terms of Appointment

Ms. Wang has entered into a service agreement with the Company as an executive Director for a term of three years commencing on 1 July 2026, and her appointment is subject to retirement by rotation and re-election at the forthcoming annual general meeting of the Company in accordance with the articles of association of the Company.

Pursuant to the service agreement, Ms. Wang is entitled to a director's fee of HK$240,000 per annum, which was determined by the Board with reference to her duties, responsibilities in the Company, and the prevailing market conditions. Ms. Wang has executed a waiver letter pursuant to which she has unconditionally and irrevocably agreed to waive her entitlement to the director's fee during her term of office as an executive Director. Accordingly, she will not receive any director's fee from the Company and therefore no remuneration will be payable to her during the waiver period. The aforementioned waiver and her remuneration package will be subject to annual review by the Board and the remuneration committee.

Ms. Wang has obtained the legal advice referred to in Rule 3.09D of the Listing Rules from a firm of solicitors qualified to advise on Hong Kong law on 26 June 2026, and has confirmed that she understands her obligations as a director of a listed issuer prior to her appointment becoming effective.

Save as disclosed above, there are no other matters relating to the appointment of Ms. Wang that need to be brought to the attention of the shareholders of the Company, nor is there any other information required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to (v) of the Listing Rules.

The Board, having considered the recommendation of the nomination committee of the Company and taking into account the need to enhance the governance structure of the Company, is satisfied that Ms. Wang possesses the character, experience and integrity required to serve as an executive Director, is delighted to welcome her appointment, and is confident that she will bring valuable contributions to the Group's healthcare business.

LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS

With effect from 1 July 2026, the members of the Board of the Company will be set out as below:

Executive Directors

Mr. Ji Guangfei *(Chairman and Chief Executive Officer)*
Ms. Li Jiang *(Deputy Chairman)*
Mr. Zhang Huanping
Ms. Wang Yinqing

Non-Executive Directors

Mr. Yuan Feng
Mr. Chung Cheuk Fan Marco

Independent non-executive Directors

Mr. Zhou Jiannan *(Lead INED)*
Ms. Hu Zhaoxia
Mr. Lyu Aiping

The Company has four Board committees, and with effect from 1 July 2026, the membership of which will be as follows:

Committee / Name of Directors	Audit Committee	Nomination Committee	Remuneration Committee	Corporate Governance Committee
Executive Directors				
Mr. Ji Guangfei		chairman	member	
Ms. Li Jiang				
Mr. Zhang Huanping				chairman
Ms. Wang Yinqing				
Non-executive Directors				
Mr. Yuan Feng				
Mr. Chung Cheuk Fan Marco				
Independent non-executive Directors				
Mr. Zhou Jiannan	member	member	chairman	member
Ms. Hu Zhaoxia	chairman	member	member	
Mr. Lyu Aiping	member	member		member

By Order of the Board
Top Eminent Healthcare Group Limited
Ji Guangfei
Chairman

Hong Kong, 26 June 2026

As at the date of this announcement, the Board comprises three Executive Directors, namely Mr. Ji Guangfei (Chairman and Chief Executive Officer), Ms. Li Jiang (Deputy Chairman) and Mr. Zhang Huanping; three Non-Executive Directors, namely Mr. Li Jiong, Mr. Yuan Feng and Mr. Chung Cheuk Fan Marco; and three Independent Non-Executive Directors, namely Mr. Zhou Jiannan (Lead INED), Ms. Hu Zhaoxia and Mr. Lyu Aiping.

* *For identification purpose only*